This is a critical abstract of an economic evaluation that meets the criteria for inclusion on NHS EED. Each abstract contains a brief summary of the methods, the results and conclusions followed by a detailed critical assessment on the reliability of the study and the conclusions drawn.
Study design
The study was a retrospective within-group comparison study in which subjects served as their own controls. The clinical CSF specimens were submitted to the Molecular microbiology laboratory for the diagnosis of HSV CNS disease by PCR. The PCR products were tested using the conventional Southern blotting and the four MTP systems. The period of observation was not reported.
Analysis of effectiveness
All specimens included in the initial study sample were taken into account in the effectiveness study. The primary outcome measures used in the analysis were the sensitivity and specificity of each alternative and the turnaround time for amplicon identification for each alternative.
Effectiveness results
The effectiveness results were as follows:
Of the 86 CSF specimens tested, 54 were HSV DNA positive and 32 were HSV DNA negative by conventional Southern blotting methods.
Compared with Southern blotting, the sensitivity and specificity for each MTP system were as follows:
PrimeCapture system, sensitivity 63.0% and specificity 100%; Quanti-PATH system, sensitivity 98.2% and specificity 96.9%; GEN-ETI-K system, sensitivity 98.2% and specificity 100.0%; and
Mayo system, sensitivity 100.0% and specificity 96.9%. Southern blotting, followed by probe hybridisation, required a minimum of 15 hours for amplicon identification. All four MTP systems needed a test time of less than 4 hours for completion of the identification of the HSV amplicon. All four MTP systems had turnaround times 12 to 24 hours less than for Southern blotting.
Clinical conclusions
Substitution of MTP systems for Southern blotting improved turnaround time and did not compromise test sensitivity.
Measure of benefits used in the economic analysis
The authors did not develop a summary benefit measure and health outcomes were left disaggregated. Thus, a costconsequences analysis (CCA) was performed.
Direct costs
The cost analysis compared Southern blotting versus the Mayo MTP system. Direct costs were determined on an annualised basis and an estimated annual volume of 3,040 procedures. The cost/resource boundary adopted in the study was not stated. Direct costs included the costs for test kits, materials, reagents, and equipment and laboratory personnel salaries. Eight percent was added to each direct cost to cover utilities. Variable allied health effort (hands-on time) was calculated per specimen. Fixed effort (specimen processing, buffer preparation, maintenance, bench cleaning, and data entry) was calculated on a per-day basis. Each procedure was outlined on a flowchart and timed by laboratory personnel. Costs and quantities were not reported separately. Discounting was not necessary as costs were incurred over a short time frame. The price year was not explicitly stated but is likely to have been 1996.
